A distinct natural killer (NK) cell subset, termed CLL_NK, is a precursor to effector NK phenotypes and serves as a critical immunologic marker in chronic lymphocytic leukemia (CLL), offering ...

The FDA approved an expanded access program for troculeucel, making the treatment available to patients outside clinical trials.